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The Obesity Paradox in
Aortic Stenosis
To Be or Not To Be*
Jean G. Dumesnil, MD, Philippe Pibarot, DVM, PHD
Québec, CanadaIn this issue of the Journal, Rogge et al. (1) publish a substudy
of the SEAS (Simvastatin Ezetimibe in Aortic Stenosis) trial
that examined whether overweight and obesity might impact
outcome in patients with aortic valve stenosis (AS). For this
purpose, 1,664 patients enrolled in the trial were grouped
according to their baseline body mass index (BMI), and
cardiovascular outcomes were recorded during an average
follow-up of 4.3 years. As expected and previously reported in
other studies (2), overweight and obese patients had higher
prevalence of hypertension, more abnormal left ventricular
(LV) geometry, and lower stress-corrected midwall short-
ening compared with normal weight patients. Surprisingly,
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however, in univariable Cox regression analysis and an initial
multivariable Cox regression model adjusting for sex,
smoking, hypertension, LV geometry, LV ejection fraction,
mean aortic gradient, and randomized study drug treatment,
the overweight group of patients (i.e., BMI 25.0 to 29.9 kg/m2)
were found to have lower rates of ischemic cardiovascular
(CV) events and AS-related events compared with the
normal weight group (i.e., BMI 18.5 to 24.9 kg/m2),
whereas obesity (i.e., BMI >30.0 kg/m2) did not signiﬁ-
cantly inﬂuence the rates of these events. Moreover, in this
ﬁrst series of multivariable models, the higher BMI classes
were not associated with statistically signiﬁcant increases in
CV or total mortality or combined hospital stay for heart
failure and death from any cause. In contrast, only when age
was added to the covariates in a second series of Cox
regression models did the association between overweight
and lower rates of AS-related and ischemic CV events
become statistically nonsigniﬁcant. Furthermore, in this
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death from any cause and a 42% to 69% higher risk of
combined hospital stay for heart failure and death from any
cause.
Several recent studies in different types of populations
(3–5) have indeed reported that, despite a higher prevalence
of well-recognized risk factors such as hypertension and
dyslipidemia, overweight and/or obese patients might actu-
ally have outcomes better than or equal to normal weight
patients. Such ﬁndings have been termed the “obesity
paradox” and have generated much discussion with regard
to interpretation and therapeutic implications. The ﬁndings
of Rogge et al. (1) are very instructive within this context,
because they illustrate that, depending on the type of sta-
tistical adjustment that is used, completely different inter-
pretations can be derived from the same dataset, and they
also provide us with the opportunity to further reﬂect on this
intriguing and unresolved paradox.
BMI: Time to Take Another Look?
In the National Institutes of Health–Centers for Disease
Control guidelines (6), the recommendations of weight loss
to lower elevated blood pressure or to lower elevated levels
of total cholesterol, low-density lipoprotein cholesterol, and
triglycerides and to raise low levels of high-density lipo-
protein cholesterol in overweight and obese persons are
given a category A level of evidence. By contrast, the use of
the BMI to assess overweight and obesity is only given
a category C level of evidence, and to our knowledge, these
recommendations and their levels of evidence have not been
revised since 1998. Before that time, the National Institutes
of Health consensus since 1985 had been to deﬁne
overweight-obesity as a BMI of 27.8 or greater for men and
27.3 or greater for women. Very recently, Flegal et al. (7)
performed a systematic review and meta-analysis of associ-
ations between standard National Heart, Lung, and Blood
Institute BMI categories for overweight and obesity and all-
cause mortality in a sample of more than 2.88 million
individuals from the general population with more than
270,000 deaths. The results show that mortality was sig-
niﬁcantly lower among those who were overweight (hazard
ratio: 0.94, 95% conﬁdence interval: 0.91 to 0.96), com-
pared with normal weight individuals, and they did not
observe higher mortality in individuals with grade I obesity.
This study thus seems to further conﬁrm the existence of an
obesity paradox to the extent that the hitherto arbitrarily
deﬁned limits of normalcy might have to be re-examined.
For instance, and as appropriately emphasized in the ac-
companying editorial by Heymsﬁeld and Cefalu (8), the
lowest all-cause mortality in many studies is observed
between a BMI of 22 and 25 kg/m2, whereas persons with
a BMI between 18.5 and 22 kg/m2 have higher mortality.
Hence, the higher mortality observed in the “normal” group
than in the overweight group could be due to the average
resulting from combining persons in the lowest mortality
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greater mortality (i.e., BMI of 18.5 to 22 kg/m2). Finally,
the epidemic increase in type 2 diabetes that has accompa-
nied the overall increase in BMI in the general population is
often invoked as an argument in favor of the guidelines, but
it can also be mentioned that general life expectancy has also
increased in record proportions during the same period and
that other factors such as the age at which type 2 diabetes
will develop might enter into consideration.
The use of BMI as a predictor of mortality is based on the
postulate that, because it predisposes to risk factors such as
hypertension, dyslipidemia, and type 2 diabetes known to
have a direct relation with mortality, it should thus also be
a good predictor of mortality. However, there is no direct
causal pathway between an increased BMI and these risk
factors, and it is highly probable that the susceptibility of
a particular individual to the ill effects of a given level of
BMI is also inﬂuenced by other factors, such as genetic
background, sex, the distribution of fat (visceral vs. sub-
cutaneous), lifestyle, and the like. As emphasized by Rogge
et al. (1), waist circumference was unfortunately not mea-
sured in the SEAS trial such that an unknown proportion of
the cohort likely had a more benign form of weight surplus
and that the ﬁndings with regard to the metabolic syndrome
might thus have limited value. The BMI is a measure of
total adiposity, but it does not discriminate between visceral
fat that likely has a harmful effect versus subcutaneous fat
that might be protective. Further studies are thus needed to
elucidate the respective impact of visceral versus subcuta-
neous adiposity on outcomes in patients with AS.
Analyzing the Data: Pathophysiology vs. Statistics
The term paradox implies that the observations are counter
to what would be expected on the basis of physiopathology
and current concepts. Such an occurrence should, however,
prompt further analysis and reﬂection rather than accepting
the ﬁndings at face value. Hence, the ﬁrst statistical model
used by Rogge et al. (1) suggested that being overweight had
a protective effect with regard to adverse outcomes and that
obesity had no effect, even though both overweight and
obesity had higher prevalence of hypertension, high fasting
glucose, and LV hypertrophy, which are anomalies usually
associated with poorer prognosis. However, in view of this
result, several observations must be made. First, at the
outset, exclusion criteria for the SEAS trial included any
indication for statin use, thus excluding patients with dys-
lipidemia, diabetes, or known ischemic heart disease; and the
overweight and/or obese patients in this cohort can thus be
considered to be low-risk compared with other cohorts.
Second, a very high proportion of the overweight (85%) and
obese (95%) had hypertension, which was also included in
the multivariable model; the analysis with regard to BMI is
thus possibly over-adjusted, because hypertension can be
considered to be in the causal pathway between obesity and
mortality (7) and because it was present in such a highproportion of the overweight and obese patients. Third, in
contrast, age was not included in the initial multivariable
analysis, although the overweight patients were signiﬁcantly
younger than the normal weight patients; because age is not
considered to be in the causal pathway between overweight/
obesity and adverse outcomes, the ﬁrst model can thus also
be seen as having possibly been under-adjusted (7). Finally,
the ischemic CV and AS-related events in this study were
largely driven by the occurrence of aortic valve replacement
and/or coronary artery bypass graft surgery; these inter-
ventions are not naturally occurring events but rather
decided subjectively by the treating physician on the basis of
criteria that might differ from one patient to another. It
cannot be assumed, for instance, that physicians are equally
aggressive in treating normal weight versus overweight or
obese patients.
Fortunately, however, Rogge et al. (1) had the foresight to
use a second multiple Cox regression model that included age
as a variable. In so-doing, the interpretation of the results and
the conclusions that had been drawn from the ﬁrst model
were completely modiﬁed to the extent that the so-called
obesity paradox was no longer present and that, overall, the
ﬁndings of the study were more consistent with current
pathophysiological concepts. Hence, potential clinical im-
plications of the ﬁndings also seemed to be completely
different. Because it still included hypertension, the second
model might still have been over-adjusted, but the results
with regard to BMI would likely not have changed signiﬁ-
cantly if it had been excluded. As with most randomized
clinical trials, the sample of patients recruited in the SEAS
trial is a highly selected subset of the general population with
AS. In particular, patients with hypercholesteromia, dia-
betes, and coronary artery disease were under-represented
or not represented in this trial, whereas patients with
hypertension were likely over-represented. Hence, the results
obtained from the SEAS trial might not be directly trans-
posable to the general population, and given that a large
proportion of patients with the “at-risk” obesity were
excluded from this trial, it is probable that in such a pop-
ulation, the impact of BMI on outcomes is more important
than what is reported in the present paper.
Conclusions
Rogge et al. (1) are to be commended for a ﬁne study that
demonstrates the extreme caution that should be exercised
when facing results that seem to be paradoxical in light of
currents concepts and physiopathology. Obviously, this topic
needs further investigation to the extent of questioning
currently used values for BMI and even the wisdom of using
this parameter as an independent predictor of mortality. The
statistical analysis of results should also be exhaustive and
logical. Finally, it should be emphasized that the beneﬁts
of weight loss still have a category A level of evidence. By
contrast, the apparent “obesity paradox” reported in many
studies requires further investigation and should not be
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recommendations.Reprint requests and correspondence: Dr. Jean G. Dumesnil,
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